ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Articles tagged with "Research"

Are ANAs More Prevalent in the U.S. Now Than in the Past?

  |  

According to a new study, the prevalence of anti-nuclear antibodies (ANAs), the most common biomarker of autoimmunity in the U.S., has increased considerably in recent years among adolescents aged 12–19 years, in both sexes (especially in men), older adults (age ≥50 years) and non-Hispanic whites…

9/11 Survivors at Increased Risk for Autoimmune Disease

  |  

Miller-Archie et al. set out to determine whether dust exposure and PTSD are associated with an increased risk of systemic autoimmune disease in a 9/11-exposed cohort not included in previous studies of members of the Fire Department of New York and whether this association differs between 9/11 responders and community members.

Finding Opportunity Through Challenge: Q&A with Vaneet K. Sandhu, MD, FACR, RhMSUS

  |  

The COVID-19 global pandemic is forcing telemedicine-only connections with patients and bringing existing rheumatology research to a standstill. However, these challenges are spurring opportunity and innovation, according to Vaneet K. Sandhu, MD, FACR, RhMSUS, director of rheumatology clinical operations at Riverside University Health System and associate fellowship program director in rheumatology at Loma Linda University…

COVID-19 Pandemic Leads Big Drugmakers to Hit Pause on Clinical Trials

Reuters Staff  |  

(Reuters)—U.S. drugmakers Eli Lilly and Co. and Bristol Myers Squibb said they are delaying the start of new clinical trials in part to free up doctors and healthcare facilities to deal with the surge in patients infected with the new coronavirus. Lilly and Bristol are the biggest drugmakers yet to announce clinical trial delays in…

A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

  |  

Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.

The Third Choice: The Predatory Journal Scam

  |  

“Greetings of the day!” My email account used to be flooded by these cheerful salutations, referring to me as an esteemed colleague or a thought leader. I have to admit: at first, I enjoyed receiving these messages. Normally, when I log into my email account, I’m greeted by messages—punctuated by red, capital letters—that announce dire…

Emerging Biomarkers for Lupus

  |  

ATLANTA—When it comes to identifying reliable biomarkers that can predict worsening illness or help point to proper treatment, it’s hard to imagine a more vexing disease than systemic lupus erythematosus (SLE), said Jill P. Buyon, MD, director of the Lupus Center at New York University Langone Medical Center, in the 2019 ACR/ARP Annual Meeting session…

Seq & Ye Shall Find

  |  

I nodded, gravely. I was recently privileged to attend a symposium on eosinophils. I realize that this sounds odd. And it was odd, mainly because I’m not an eosinophil expert. Still, they were in need of someone who knew something about eosinophilic granulomatosis with polyangiitis, so I managed to sneak in through the back door….

New ACR/EULAR IgG4 Classification Criteria Introduced

  |  

Immunoglobulin G4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic and pathologic data is required for diagnosis. ACR/EULAR classification criteria for IgG4-RD have now been developed and validated in a large cohort of patients…